11
TITLE: Progression of Quality of Life in Patients with Plaque Psoriasis Who Achieved Three or More Years of Complete Skin Clearance with Guselkumab Treatment: a Post hoc Analysis of the VOYAGE 1 Clinical Trial
AUTHORS: Puig, Luis; Costanzo, Antonio; de Jong, Elke M. G. J.; Torres, Tiago; Warren, Richard B.; Wapenaar, Robert; Wegner, Sven; Gorecki, Patricia; Gramiccia, Talia; Jazra, Maria; Buyze, Jozefien; Conrad, Curdin;
PUBLISHED: 2024, SOURCE: DERMATOLOGY AND THERAPY
INDEXED IN: Scopus WOS
12
TITLE: Extended Half-life Antibodies: A Narrative Review of a New Approach in the Management of Atopic Dermatitis
AUTHORS: Yilmaz, Orhan; Torres, Tiago;
PUBLISHED: 2024, SOURCE: DERMATOLOGY AND THERAPY, VOLUME: 14, ISSUE: 9
INDEXED IN: Scopus WOS CrossRef
IN MY: ORCID
13
TITLE: Lebrikizumab is an effective treatment for moderate-to-severe atopic dermatitis in patients ≥60 years of age  Full Text
AUTHORS: Armstrong, April; Zirwas, Matthew; Napolitano, Maddalena; Torres, Tiago; Staumont Salle, Delphine; Atwater, Amber Reck; Dossenbach, Martin; Agell, Helena; Chen, Sherry; Qiao, Meihua; Pierce, Evangeline; Piruzeli, Maria Lucia Buziqui; Mostaghimi, Arash;
PUBLISHED: 2024, SOURCE: Revolutionizing Alopecia Areata, Vitiligo and Eczema Conference (RAVE) in BRITISH JOURNAL OF DERMATOLOGY, VOLUME: 191
INDEXED IN: WOS
14
TITLE: Emerging Biologic Therapies for the Treatment of Atopic Dermatitis  Full Text
AUTHORS: Alvarenga, Jose Miguel; Bieber, Thomas; Torres, Tiago;
PUBLISHED: 2024, SOURCE: DRUGS
INDEXED IN: Scopus WOS CrossRef
IN MY: ORCID
15
TITLE: Real-World Evidence on Dose Spacing of IL-23 Inhibitors in the Treatment of Psoriasis  Full Text
AUTHORS: Luz, Martim; Torres, Tiago;
PUBLISHED: 2024, SOURCE: AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
INDEXED IN: Scopus WOS CrossRef
IN MY: ORCID
16
TITLE: Upadacitinib for the treatment of psoriatic arthritis
AUTHORS: Fonseca, D; Nogueira, M; Torres, T;
PUBLISHED: 2023, SOURCE: Drugs in Context, VOLUME: 12
INDEXED IN: Scopus CrossRef: 3
IN MY: ORCID
17
TITLE: Speed of clinical improvement in the real-world setting from patient-reported Psoriasis Symptoms and Signs Diary: Secondary outcomes from the Psoriasis Study of Health Outcomes through 12 weeks
AUTHORS: Reich, A.; Pinter, A.; Maul, J. T.; Vender, R. B.; Torres, T.; Brnabic, A.; Haustrup, N.; Reed, C.; Schuster, C.; Riedl, E.;
PUBLISHED: 2023, SOURCE: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, VOLUME: 37, ISSUE: 9
INDEXED IN: Scopus WOS CrossRef: 3
IN MY: ORCID
18
TITLE: Viewpoint about biologic agents for psoriasis: are they immunosuppressants or immunomodulators?
AUTHORS: Metko, Dea; Torres, Tiago; Vender, Ronald;
PUBLISHED: 2023, SOURCE: JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, VOLUME: 51, ISSUE: 6
INDEXED IN: Scopus WOS CrossRef: 1
IN MY: ORCID
19
TITLE: Effectiveness of secukinumab for the treatment of erythrodermic psoriasis: Multicentre study in daily practice
AUTHORS: Reymundo, A.; Armesto, S.; Rodriguez, L.; Baniandres, O.; Sahuquillo Torralba, A.; Torres, T.; de la Cueva, P.; Llamas Velasco, M.; Dauden, E.;
PUBLISHED: 2023, SOURCE: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, VOLUME: 37, ISSUE: 12
INDEXED IN: Scopus WOS CrossRef
IN MY: ORCID
20
TITLE: Abrocitinib for the treatment of atopic dermatitis
AUTHORS: Ana Maria Lé; Melinda Gooderham; Tiago Torres;
PUBLISHED: 2023, SOURCE: Immunotherapy, VOLUME: 15, ISSUE: 16
INDEXED IN: Scopus CrossRef: 2
IN MY: ORCID
Page 2 of 16. Total results: 151.